Results 1 to 10 of about 15,263 (254)

Dupilumab in children with eosinophilic esophagitis: a retrospective multicenter study

BMC Pediatrics
Background Eosinophilic esophagitis (EoE) is a chronic inflammatory disorder characterized by symptoms of esophageal dysfunction and eosinophil-predominant inflammation. Dupilumab is a human monoclonal antibody that targets both IL-4 and IL-13 signaling.
Mohammed Hasosah, Ghassan Sukkar, Asharf AlSahafi, Ali Zaidan, Nouf Ghous, Abdulmajed Alshahrani, Ziyad Al Zahrani, Naif Hasosah, Mansour Qurashi, Loie Goronfolah, Ali Alsharief, Nagla Kamal   +11 more
doaj   +1 more source

Dupilumab-Associated Blepharoconjunctivitis with Giant Papillae

International Medical Case Reports Journal, 2020
Filippos Vingopoulos, Douglas R Lazzaro New York University School of Medicine, Department of Ophthalmology, New York, NY 10017, USACorrespondence: Douglas R LazzaroNew York University School of Medicine, Department of Ophthalmology, 222 East 41st Street,
Vingopoulos F, Lazzaro DR
doaj  

Friend or Foe? Eosinophilic Granulomatosis with Polyangiitis (EGPA) Onset After Dupilumab: Report of Two Cases and a Narrative Review of the Literature

Rheumato
Background/Objectives: Dupilumab is a fully human IgG4 monoclonal antibody targeting the interleukin-4 receptor α subunit, inhibiting interleukin-4 and interleukin-13 signalling, and suppressing type 2 inflammation.
Alessia Gatti, Giulia Fontana, Jacopo Mora, Franco Franceschini, Ilaria Cavazzana, Paola Toniati, Francesca Regola   +6 more
doaj   +1 more source

Re‐engagement, quality of life, and burden of treatment in adults on dupilumab for severe atopic dermatitis—A mixed methods study

Skin Health and Disease
Background Targeted biologic therapies have revolutionised the treatment of severe atopic dermatitis (AD). Objectives To assess effects of dupilumab on patient re‐engagement, quality of life (QOL), and burden of treatment (BOT) in severe AD.
Emma Porter, Cathal O’Connor, Michelle Murphy   +2 more
doaj   +1 more source

Dupilumab‐Induced Erythrodermic Psoriasiform Dermatitis in Chronic Actinic Dermatitis: Case Report and Innovative Treatment Approach

Clinical Case Reports
The off‐label use of dupilumab has proven to be an effective treatment option for severe chronic actinic dermatitis (CAD). We present the first case of CAD presenting with dupilumab‐induced erythrodermic psoriasiform dermatitis.
Joe Khodeir, Maya Habre
doaj   +1 more source

Long-term outcomes of dupilumab therapy in severe asthma: A retrospective, multicenter, real-world study

Journal of Allergy and Clinical Immunology: Global
Background: Dupilumab is an IL-4Rα antibody approved for treatment of severe asthma. Real-world data on the continuation and cessation patterns of dupilumab and long-term treatment efficacy are scarce.
Carlo Mümmler, MD, Alexandra Lenoir, MD, Jeremias Götschke, MD, Michael Gerckens, MD, Merle Kaiser, MD, Moritz Kayser, MD, Nora Drick, MD, Hendrik Suhling, MD, Leonie Biener, MD, Carmen Pizarro, MD, Dirk Skowasch, MD, Nikolaus Kneidinger, MD, PhD, Jürgen Behr, MD, Katrin Milger, MD   +13 more
doaj   +1 more source

Rosacea-like skin reaction under treatment with dupilumab for atopic dermatitis

Journal of Dermatological Treatment
Purpose Dupilumab is a widely recommended treatment for moderate-to-severe atopic dermatitis (AD), with known ocular side effects but less frequent cutaneous reactions.Material and methods This case report details a 52-year-old female patient with atopic
C. Grote, F. Zirkenbach, J. N. Wagner, M. Augustin   +3 more
doaj   +1 more source

Suspensión de dupilumab en dermatitis atópica. ¿es una opción la suspensión? Seguimiento de 12 casos

Revista de la Asociación Colombiana de Dermatología y Cirugía Dermatológica
Antecedentes: Dupilumab es el primer tratamiento biológico aprobado para la dermatitis atópica (DA) moderada a severa con excelente perfil de seguridad y eficacia pero hasta el momento con poca literatura sobre la duración de tratamiento.   Objetivo:
Mirian Casas-Vargas, Cindy Cáceres-Salamanca, María Fernanda Ordóñez-Rubiano   +2 more
doaj   +1 more source

Summary of Research: Immunogenicity of Dupilumab in Adult and Pediatric Patients with Atopic Dermatitis

Dermatology and Therapy
Summary of the original article “Immunogenicity of Dupilumab in Adult and Pediatric Patients with Atopic Dermatitis.” Dupilumab is a monoclonal antibody used to treat atopic dermatitis (AD) in patients 6 months and older.
Matthew P. Kosloski, Ching-Ha Lai, Michael A. Partridge, Vanaja Kanamaluru, Ashish Bansal, Brad Shumel, Marius Ardeleanu, Hong Yan, Christine Xu, Ainara Rodríguez Marco, Jing Xiao, Faisal A. Khokhar, Guy Gherardi, Elisa Babilonia, Bolanle Akinlade, Albert Torri, John D. Davis   +16 more
doaj   +1 more source

Dupilumab versus Lebrikizumab Demonstrates Greater Likelihood of Achieving and Maintaining Improvements in Efficacy Outcomes Using a Placebo-Adjusted Indirect Treatment Comparison

Dermatology and Therapy
Introduction Dupilumab and lebrikizumab have demonstrated efficacy in atopic dermatitis (AD) clinical trials; however, no direct comparisons exist. Methods Efficacy outcome achievement (dupilumab and lebrikizumab with topical corticosteroids [TCS]) at 16 
Sonja Ständer, Andreas Pinter, Firas G. Hougeir, Patricia Guyot, Yingxin Xu, Amy H. Praestgaard, Nick Freemantle, Ana B. Rossi, Gaëlle Bégo-Le-Bagousse, Zhixiao Wang, Kerry Noonan, Mike Bastian   +11 more
doaj   +1 more source